Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview
Aytu Biopharma Inc AYTU.O is expected to show a fall in quarterly revenue when it reports results on September 22 for the period ending June 30 2026
The Denver Colorado-based company is expected to report a 18.9% decrease in revenue to $12.276 million from $15.14 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aytu Biopharma Inc is for a loss of 32 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.46 | -0.51 | -0.53 | Missed | -3.9 |
Dec. 31 2026 | -0.60 | -0.60 | -1.05 | Missed | -75 |
Sep. 30 2025 | -0.23 | -0.23 | 0.21 | Beat | 191.3 |
Jun. 30 2025 | -0.04 | -0.04 | -2.92 | Missed | -7,862.9 |
Mar. 31 2025 | -0.17 | -0.17 | 0.21 | Beat | 223.5 |
Dec. 31 2024 | -0.28 | -0.28 | -0.26 | Beat | 7.1 |
Sep. 30 2024 | -0.34 | -0.34 | 0.44 | Beat | 229.4 |
Jun. 30 2024 | -0.45 | -0.82 | Missed | -82.2 |
This summary was machine generated September 18 at 20:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)